ASIAN C T Market to be more explored .....
0 views
Skip to first unread message
FAISAL ZAIDI
Sep 13, 2007, 1:45:49 AM9/13/07
to IndiaClinic...@googlegroups.com
Full potential of outsourcing to Asia yet to be grasped
12/09/2007 - Outsourcing to Asia has become a common practice among the pharma industry but the trend has still some way to run, according to recently released market research.
Competition from generics and pricing pressures to develop new drugs continues to drive drug makers to outsource to lower cost but highly effective companies in Asia, a report published by PricewaterhouseCoopers (PwC) found.
However, "outsourcing to the region has not reached its highest point due to quality and intellectual property (IP) issues and there has been an ebbing of the tide," Dan Bartholomew, senior managing director with PwC's pharmaceutical and life sciences practice, told Outsourcing-Pharma.com.
A majority of the pharmaceutical companies surveyed (56 per cent) said the industry is failing to fully grasp the potential for outsourcing and are missing opportunities for shared development and improvement.
Bartholomew stressed that outsourcing in general is a well accepted process in particular for manufacturers who are very friendly with outsourcing processes.
As a result, he said, pharma companies have recently made efforts and put structures in place in order to adapt to the Asian market and the tide is now rising faster.
In terms of outsourcing, the two biggest players are India, closely followed by China.
But there is also a number of up-and-coming countries including Singapore, which is a fast-moving destination for outsourcing in particular for R&D and clinical trials .
"The main reason for that is the development of R&D biocentres and campuses, and facilities which have recently been put in place. The government has been very friendly in terms of investment," said Bartholomew.
South Korea has also a lot to offer and although the market is still in its infancy, there are facilities in place and outsourcing availabilities, he added.
Looking forward, Bartholomew said: "We are expecting the outsourcing trend to continue but not as fast due to quality and IP issues. When these issues are resolved, pharma companies need to make sure they have the management, structure policy and the people in place in Asia."
But all of those countries, and in particular China and India, are taking these issues very seriously and have been showing efforts of late to improve things.
The two countries have for example recently taken steps to be more transparent in terms of the running of clinical trials.
The findings of the report called "Gearing Up for a Global Gravity Shift: Growth, Risk and Learning in the Asia Pharmaceutical Market" were bare based on a survey of 185 senior pharma executives, half of them based in China, India, South Korea and six other Asian countries.
12/09/2007 - Outsourcing to Asia has become a common practice among the pharma industry but the trend has still some way to run, according to recently released market research.
Competition from generics and pricing pressures to develop new drugs continues to drive drug makers to outsource to lower cost but highly effective companies in Asia, a report published by PricewaterhouseCoopers (PwC) found.
However, "outsourcing to the region has not reached its highest point due to quality and intellectual property (IP) issues and there has been an ebbing of the tide," Dan Bartholomew, senior managing director with PwC's pharmaceutical and life sciences practice, told Outsourcing-Pharma.com.
A majority of the pharmaceutical companies surveyed (56 per cent) said the industry is failing to fully grasp the potential for outsourcing and are missing opportunities for shared development and improvement.
Bartholomew stressed that outsourcing in general is a well accepted process in particular for manufacturers who are very friendly with outsourcing processes.
As a result, he said, pharma companies have recently made efforts and put structures in place in order to adapt to the Asian market and the tide is now rising faster.
In terms of outsourcing, the two biggest players are India, closely followed by China.
But there is also a number of up-and-coming countries including Singapore, which is a fast-moving destination for outsourcing in particular for R&D and clinical trials .
"The main reason for that is the development of R&D biocentres and campuses, and facilities which have recently been put in place. The government has been very friendly in terms of investment," said Bartholomew.
South Korea has also a lot to offer and although the market is still in its infancy, there are facilities in place and outsourcing availabilities, he added.
Looking forward, Bartholomew said: "We are expecting the outsourcing trend to continue but not as fast due to quality and IP issues. When these issues are resolved, pharma companies need to make sure they have the management, structure policy and the people in place in Asia."
But all of those countries, and in particular China and India, are taking these issues very seriously and have been showing efforts of late to improve things.
The two countries have for example recently taken steps to be more transparent in terms of the running of clinical trials.
The findings of the report called "Gearing Up for a Global Gravity Shift: Growth, Risk and Learning in the Asia Pharmaceutical Market" were bare based on a survey of 185 senior pharma executives, half of them based in China, India, South Korea and six other Asian countries.
Reply all
Reply to author
Forward
0 new messages